ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Cancer

Roche pays $2.4 billion for rest of Foundation Medicine

by Lisa Jarvis
June 23, 2018 | APPEARED IN VOLUME 96, ISSUE 26

Roche will pay $2.4 billion to acquire the portion of genomic profiling firm Foundation Medicine that it doesn’t already own. Foundation develops tests that pinpoint the genetic defect driving a person’s cancer, allowing tailored treatments. Roche bought a majority stake in the firm in early 2015 for $1.3 billion. The deals dovetail with Roche’s strategy to focus on personalized health care. Foundation will operate as a separate entity.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment